Advancing the science of hope

Andrew Powaleny   |     June 13, 2016   |   SHARE THIS

Developing new medicines is a challenging undertaking, and the science is only getting harder. As our understanding of science grows, so does the complexity of developing new medicines, particularly as treatments are increasingly becoming personalized to individual patients. Yet through it all, America’s biopharmaceutical researchers and scientists are tireless in their pursuit of new treatments and cures for patients.


Every day, patients around the world are living longer, healthier lives thanks to innovative medicines developed by America’s biopharmaceutical research companies. New treatments and cures for diseases such as hepatitis C, high cholesterol and cancer are transforming treatment for patients. With over 7,000 medicines in development around the globe, patients have more reason to be hopeful than ever before.

As a new effort on our From Hope to Cures platform, today we’re excited to continue spotlighting the Science of Hope by America’s biopharmaceutical industry. This effort includes a new webpage that provides resources on the complexity behind promising scientific advances. It also discusses new and powerful tools to improve and accelerate the development of safe and effective medicines for the 21st century.

Within the new the new webpage, you will find the following information:

  • Scientific Advances: Explore the progress the biopharmaceutical industry has made in medical research and development.
  • In the Pipeline: Learn about promising new medicines in development.
  • People Behind the Science: Find out more about the men and women dedicated to bringing new treatments and cures to patients.
  • Glossary of Terms: Look up definitions for commonly-used terms related to medical research and biopharmaceutical innovation.

To learn more about what America’s biopharmaceutical researchers and scientists are doing to advance the science of hope, visit: www.fromhopetocures.org/scienceofhope.

Andrew Powaleny

Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organization's scientific communications. Before joining PhRMA in 2015, he worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; most recently serving on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.

Topics: Research and Development, FDA, FDA Modernization

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates